Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

@article{Bacigalupo2010AllogeneicHS,
  title={Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type},
  author={Andrea Bacigalupo and Mariella Sorarů and Alida Dominietto and Samantha Pozzi and Simona Geroldi and M Teresa van Lint and Adalberto Ibatici and A M Raiola and Francesco Frassoni and Francesco De Stefano and Simonetta Verdiani and Lucia Casarino and Giovanni Barosi},
  journal={Bone Marrow Transplantation},
  year={2010},
  volume={45},
  pages={458-463}
}
A total of 46 patients with primary myelofibrosis (PMF) (median age 51 years), underwent an allogeneic hemopoietic SCT (HSCT) after a thiotepa-based reduced-intensity conditioning regimen. The median follow-up for surviving patients is 3.8 years. In multivariate analysis, independent unfavorable factors for survival were RBC transfusions >20, a spleen size >22 cm and an alternative donor—24 patients had 0–1 unfavorable predictors (low risk) and 22 patients had 2 or more negative predictors… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Guideline for the diagnosis and management of myelofibrosis.

British journal of haematology • 2012
View 4 Excerpts
Highly Influenced

The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2017

Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2016

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2007

Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation • 2006

Similar Papers

Loading similar papers…